Solange Peters, MD, PhD of Lausanne University Hospital discusses the impact of Checkmate-026 on current cancer research, stating the data encourages clinicians to move and assess the biomarkers in all ongoing trials. She also argues that the biomarker can help predict which patients will benefit from early therapeutic treatments. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.
Data Encourages Clinicians to Move and Assess These Biomarkers in All Ongoing Trials
